Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prebet

Showing results (11-20 of 99) with videos related to

Pageof 10
Sort By:
Expert Opinion on Pharmacotherapy|July 5, 2017
Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settingsNatalie Uy, Abhay Singh, Steven D Gore, et al.
Leukemia|May 28, 2021
Current challenges and unmet medical needs in myelodysplastic syndromesUwe Platzbecker, Anne Sophie Kubasch, Collin Homer-Bouthiette, et al.
Leukemia Research|March 9, 2020
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemiaElizabeth A Griffiths, Hetty E Carraway, Namrata S Chandhok, et al.
Current Opinion in Hematology|January 12, 2019
What are the most promising new agents in myelodysplastic syndromes?Namrata S Chandhok, Prajwal C Boddu, Steven D Gore, et al.
Expert Review of Hematology|February 25, 2014
Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?Amer M Zeidan, Thomas Prebet, Ehab Saad Aldin, et al.
Journal of Personalized Medicine|January 7, 2021
Definition of Personalized Medicine and Targeted Therapies: Does Medical Familiarity Matter?Valentyn Fournier, Thomas Prebet, Alexandra Dormal, et al.
Journal of Cutaneous Pathology|June 30, 2019
Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid diseaseEmily Coleman, Gauri Panse, Shawn Cowper, et al.
Expert Review of Hematology|January 7, 2016
New Insights into the Pathogenesis of MDS and the rational therapeutic opportunitiesAbdallah Abou Zahr, Carolina Bernabe Ramirez, Jocelyn Wozney, et al.
Anti-Cancer Agents in Medicinal Chemistry|January 24, 2012
Design of N-substituted amino caproic hydroxamic acid histone deacetylase inhibitors reveal an essential role for cap atomic compositionJean M Brunel, Chanaz Salmi-Smail, Audrey Restouin, et al.
Plos Genetics|October 11, 2016
Epigenetics in Cancer: A Hematological PerspectiveMaximilian Stahl, Nathan Kohrman, Steven D Gore, et al.
Pageof 10

Showing results (11-20 of 99) with videos related to

Sort By:
Pageof 10
Expert Opinion on Pharmacotherapy|July 5, 2017
Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settingsNatalie Uy, Abhay Singh, Steven D Gore, et al.
Leukemia|May 28, 2021
Current challenges and unmet medical needs in myelodysplastic syndromesUwe Platzbecker, Anne Sophie Kubasch, Collin Homer-Bouthiette, et al.
Leukemia Research|March 9, 2020
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemiaElizabeth A Griffiths, Hetty E Carraway, Namrata S Chandhok, et al.
Current Opinion in Hematology|January 12, 2019
What are the most promising new agents in myelodysplastic syndromes?Namrata S Chandhok, Prajwal C Boddu, Steven D Gore, et al.
Expert Review of Hematology|February 25, 2014
Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?Amer M Zeidan, Thomas Prebet, Ehab Saad Aldin, et al.
Journal of Personalized Medicine|January 7, 2021
Definition of Personalized Medicine and Targeted Therapies: Does Medical Familiarity Matter?Valentyn Fournier, Thomas Prebet, Alexandra Dormal, et al.
Journal of Cutaneous Pathology|June 30, 2019
Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid diseaseEmily Coleman, Gauri Panse, Shawn Cowper, et al.
Expert Review of Hematology|January 7, 2016
New Insights into the Pathogenesis of MDS and the rational therapeutic opportunitiesAbdallah Abou Zahr, Carolina Bernabe Ramirez, Jocelyn Wozney, et al.
Anti-Cancer Agents in Medicinal Chemistry|January 24, 2012
Design of N-substituted amino caproic hydroxamic acid histone deacetylase inhibitors reveal an essential role for cap atomic compositionJean M Brunel, Chanaz Salmi-Smail, Audrey Restouin, et al.
Plos Genetics|October 11, 2016
Epigenetics in Cancer: A Hematological PerspectiveMaximilian Stahl, Nathan Kohrman, Steven D Gore, et al.
Pageof 10